Secondary analysis of a phase 2b trial in 1287 patients with AF: abelacimab 90 or 150 mg monthly was associated with less major or clinically relevant nonmajor bleeding than rivaroxaban both at 75 years or older (HR 0.32 and 0.40) and under 75 (HR 0.28 and 0.35).
Secondary analysisn = 1,287
Al Said et al. Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial